Table 3.

Risk of frailty and its association with any infection during follow-up, univariable and multivariable analyses.

	OR	95% CI	p-value	aOR	95% CI	p-value
Risk of frailty	1.403	0.867–2.269	0.168	1.550	0.898–2.675	0.115
Age at baseline	0.963	0.915–1.014	0.154	0.964	0.911–1.020	0.205
Biochemical disease activity	1.013	0.574–1.789	0.964	0.859	0.460–1.605	0.634
Comorbidity	1.016	0.853–1.212	0.855	0.942	0.768–1.156	0.568
Crohn’s disease	1.226	0.761–1.974	0.403	0.857	0.486–1.511	0.593
Oral corticosteroid use	1.524	0.726–3.202	0.266	1.321	0.600–2.908	0.489
Immunomodulator use	0.810	0.436–1.504	0.505	0.691	0.349–1.370	0.290
Biological therapy	2.354	1.422–3.897	0.001	2.271	1.280–4.028	0.005

Logistic regression analyses. Analyses were performed as complete case analyses; 346 patients were included in multivariable analyses [n = 170 risk of frailty, n = 76 any infection]. Frailty screening by Geriatric 8 Questionnaire, ≤14 points = risk of frailty. Biochemical disease activity: C-reactive protein ≥10 mg/L and/or faecal calprotectin ≥250 µg/g. Comorbidity measured by Charlson Comorbidity Index, continuous.